Last reviewed · How we verify

NCT04935619

Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression

Recruiting now NA Last updated 24 February 2025
What this trial tests

NA trial testing Contingency Reinforcement in Cannabis Use in 52 participants. Currently enrolling.

Timeline
21 July 2021
Primary endpoint
30 June 2027
31 August 2027

Quick facts

Lead sponsorCentre for Addiction and Mental Health
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment52
Start date21 July 2021
Primary completion30 June 2027
Estimated completion31 August 2027
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Centre for Addiction and Mental Health — full company profile →

Who can join

Adults 18 to 55, any sex, with Cannabis Use or Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore causal relationships are unclear. This study investigates the effects of cannabis abstinence over a 28-day period in patients with MDD with co-occurring CUD using a randomized controlled design, namely contingent reinforcement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cannabis Use

Currently open trials in the same condition.

Other Centre for Addiction and Mental Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04935619.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing